 NEW YORK, Aug. 05, 2020 GLOBE NEWSWIRE -- Ovid Therapeutics Inc. NASDAQ: OVID, a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Medical Officer, will participate in a panel discussion at the William Blair Biotech Focus Conference 2020. The panel is titled, New Therapies Impacting the Epilepsy Treatment Landscape, and will be held on Thursday, August 6, 2020, at 12:00 p.m. ET. A live audio webcast of the discussion can be accessed through the Events Presentations section of the Companys website at investors.ovidrx.com. An archived replay of the webcast will be available on the Companys website following the live presentation.About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Companys most advanced investigational medicine, OV101 gaboxadol, is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 soticlestat in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies DEE. For more information on Ovid, please visit and Media: Ovid Therapeutics Inc. Investor Relations Public Relations Steve Klass Burns McClellan, Inc. 212 213-0006Media: Katie Engleman 1AB 